Tagged With "OIT"

Blog Post

AAFA Elevates Patient Voice in ICER Review of New Peanut Allergy Treatments

AAFA Community Services ·
On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).
Blog Post Featured

Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut Allergy Treatments

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy.
Post
×
×
×
×